Royal Bank of Canada »

Acrivon Therapeutics shares owned by Royal Bank of Canada

Quarter-by-quarter ownership of Acrivon Therapeutics (ACRV) shares owned by Royal Bank of Canada from 13F filings

Historical chart of Royal Bank of Canada investment in Acrivon Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Acrivon Therapeutics held by Royal Bank of Canada consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Acrivon Therapeutics by Royal Bank of Canada

Quarter filed Position value Share count Share price at filing
2023-12-31 $12k 2.5k 4.73
2023-09-30 $16k 1.6k 9.90
2023-06-30 $12k 907 13.23

More positions owned by Royal Bank of Canada

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Microsoft Corporation (MSFT)
Apple (AAPL)
Toronto Dominion Bk Ont Com New (TD)
Amazon (AMZN)
Rbc Cad (RY)
Bank Of Montreal Cadcom (BMO)
Canadian Natural Resources (CNQ)
Enbridge (ENB)
UnitedHealth (UNH)
Bk Nova Cad (BNS)
NVIDIA Corporation (NVDA)
Ishares Tr Russell 2000 Etf (IWM)
Alphabet Cap Stk Cl A (GOOGL)
Visa Com Cl A (V)

View all positions for Royal Bank of Canada

Top funds holding Acrivon Therapeutics

RA Capital Management
Perceptive Advisors
Citadel Advisors
Wellington Management Company
Marshall Wace
Vanguard Group
NEA Management Company
Federated Investors
DAFNA Capital Management
Charles Schwab Investment Management
Exchange Traded Concepts
Jacobs Levy Equity Management
Jpmorgan Chase & Co
D. E. Shaw & Co
Barclays

View all funds holding Acrivon Therapeutics